Month: March 2023
-
March 28th, 2023: Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
Collaboration to develop a Granzyme B-targeted agent for PET imaging applications in inflammation and cancer indications BOSTON, March 28, 2023 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment
-
March 13th, 2023: Ratio Therapeutics Appoints Dr. Noel Monks as Head of Biology
BOSTON, March 13, 2023 /PRNewswire/ — Ratio Therapeutics Inc. (Ratio), a pharmaceutical company specializing in the development of targeted radiotherapeutics for the treatment of cancer, today announced the appointment of Dr. Noel Monks as the company’s Head of Biology. Dr. Monks joins Ratio with over 20 years